Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care.

The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 30; no. 4; pp. 4365 - 4379
Main Authors:	Mittal, Abhenil, Sridhar, Srikala S., Ong, Michael, Jiang, Di Maria
Format:	Journal Article
Published:	MDPI Apr2023
Online Access:	View this record in EBSCOhost